Â鶹ӳ»­

Aneuploidy ¡ª an abnormal number of chromosomes ¡ª is a hallmark of most human cancers and strongly associated with poor clinical outcomes. However, the biological link between aneuploidy and cancer remains incompletely understood. Increasing evidence suggests that aneuploid cells engage with the immune system in complex ways. While initially recognized as abnormal, they often develop strategies to evade immune clearance.

Our laboratory uses genetically engineered mouse models, single-cell genomics and immunological profiling to dissect how chromosome missegregation alters cell fate, signaling and the tumor immune landscape. We focus on identifying the molecular pathways that govern immune detection of aneuploid cells and the mechanisms tumors use to suppress these responses during progression.

Ultimately, our goal is to restore effective immune surveillance against aneuploid tumors by uncovering new molecular targets and developing combination immunotherapy approaches tailored to the unique biology of chromosomally unstable cancers.